



Antibodies

T7-175-T100

Monoclonal Antibody to CD22 PE-Cy™7 conjugated (100 tests)

Clone:	S-HCL-1
Isotype:	Mouse IgG2b
Specificity:	The mouse monoclonal antibody S-HCL-1 (also known as S-HCL1) recognizes CD22 (BL-CAM), a 130 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed in the cytoplasm of pro-B and pre-B lymphocytes, and on the surface of mature and activated B lymphocytes; it is lost on plasma cells, peripheral blood T lymphocytes, granulocytes and monocytes. HLDA IV; WS Code B48
Regulatory Status:	RUO
Immunogen:	Whole hairy cell leukemia cells and membrane preparation
Species Reactivity:	Human
Preparation:	The purified antibody is conjugated with tandem dye PE-Cy™7 under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
Storage Buffer:	The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide.
Storage / Stability:	Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Usage:	The reagent is designed for Flow Cytometry analysis of human blood cells using 4 µl reagent / 100 µl of whole blood or 10 ⁶ cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Expiration:	See vial label
Lot Number:	See vial label
Background:	CD22, also known as Siglec-2 (sialic acid-binding immunoglobulin-like lectin-2) is a transmembrane glycoprotein binding alpha2,6-linked sialic acid-bearing ligands. Intracellular domain of CD22 recruits protein tyrosine phosphatase SHP-1 through the immunoreceptor tyrosine-based inhibitory motifs (ITIMs), thus setting a threshold for B cell receptor-mediated activation. CD22 also regulates B-cell response by involvement in controlling the CD19/CD21-Src-family protein tyrosine kinase amplification pathway and CD40 signaling. CD22 exhibits hallmarks of clathrin-mediated endocytic pathway.

For laboratory research only, not for drug, diagnostic or other use.



Antibodies

- References:**
- *Foon KA, Todd RF 3rd: Immunologic classification of leukemia and lymphoma. Blood. 1986 Jul;68(1):1-31.
 - *Reineks EZ, Osei ES, Rosenberg A, Auletta J, Meyerson HJ: CD22 expression on blastic plasmacytoid dendritic cell neoplasms and reactivity of anti-CD22 antibodies to peripheral blood dendritic cells. Cytometry B Clin Cytom. 2009 Jul;76(4):237-48
 - *Huang J, Fan G, Zhong Y, Gatter K, Braziel R, Gross G, Bakke A: Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-Cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry. Am J Clin Pathol. 2005 Jun;123(6):826-32.
 - *James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ, Press OW: Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 2008 May 15;180(10):7028-38.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

Cy™ and CyDye™ are registered trademarks of GE Healthcare.

For laboratory research only, not for drug, diagnostic or other use.

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic
Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz